¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Immunization, yellow fever"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cat-scratch fever
    °í¾çÀÌÇÒÅ¡¿­
  • camp fever
    º´»ç¿­, ¹ßÁøÆ¼Çª½º
  • Choix fever
    ½´¾Æ¿­
  • dehydration fever
    Å»¼ö¿­
  • dengue fever
    µ­±â¿­
  • desert fever
    »ç¸·¿­
  • enteric fever
    âÀÚ¿­
  • epidemic hemorrhagic fever
    À¯ÇàÃâÇ÷¿­
  • eruptive fever
    ¹ßÁø¿­
  • essential fever
    º»Å¿­
  • ferment fever
    ¹ßÈ¿¼Ò¿­
  • fermentation fever
    ¹ßÈ¿¿­
  • fever
    ¿­
  • fever of unknown origin
    ¿øÀÎºÒ¸í¿­
  • fever stage
    À¯¿­±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cat-scratch fever
    °í¾çÀÌÇÒÅ¡¿°
  • cesspool fever
    (¢¡typhoid fever) ÀåÆ¼Çª½º
  • choix fever
    ½´¾Æ¿­
  • continued fever
    Áö¼Ó¿­
  • cottonmill fever
    (¢¡byssinosis) ¸éÆóÁõ
  • hay fever conjunctivitis
    °íÃÊ¿­°á¸·¿°
  • dehydration fever
    Å»¼ö¿­
  • dengue fever
    (¢¡dengue) µ­±â
  • desert fever
    »ç¸·¿­
  • enteric fever
    âÀÚ¿­
  • epidemic hemorrhagic fever
    À¯ÇàÃâÇ÷¿­
  • eruptive fever
    ¹ßÁø¿­, ¸ÍÃâ¿­
  • essential fever
    º»Å¿­
  • fever
    ¿­
  • factitious fever
    ÀÎÀ§¿­
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Cremean hemorrhagic fever virus
    Å©¸®¹Ì¾Æ ÃâÇ÷¿­¹ÙÀÌ·¯½º
  • Crimean hemorrhage fever
    Å©¸®¹Ì¾ÆÃâÇ÷¿­.
  • Fever
    ¿­(æð)
  • Haverhill fever
    ÇϺ£¸£Èú¿­(¡­æð).
  • Haverhill fever
    ÇϹöÈú¿­
  • Hay fever
    °íÃÊ¿­(ͽõ®æð)
  • Heerfordts disease=>uveoparotid fever
    Ç츣Æ÷¸£Æ®º´
  • Heerfordts syndrome => uveoparotid fever
    Ç츣Æ÷¸£Æ® ÁõÈıº
  • Korean hemorrhagic fever
    ½ÅÁõÈıºÃâÇ÷¿­, Çѱ¹Çü À¯Ç༺ÃâÇ÷¿­
  • Korean hemorrhagic fever
    Çѱ¹ÇüÃâÇ÷¿­.
  • Kyasanur forest fever virus
    Ű¾Æ»ç´©¸£ »ï¸²¿­¹ÙÀÌ·¯½º
  • Lassa fever
    ¶ó»ç¿­
  • Lassa fever virus
    ¶ù»ç¿­¹ÙÀÌ·¯½º
  • Malta fever
    ¸»Å¸¿­
  • Mediterranean fever
    ÁöÁßÇØ¿­ ¡ìºê·ç¼¿¶ó Áõ¡í.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • fort bragg fever => pretibial fever
  • acute yellow atrophy
    ±Þ¼º Ȳ»öÀ§Ãà(Áõ)(ÐáàõüÜßäê×õêñø) °£(ÊÜ)
  • acute yellow atrophy
    ±Þ¼º Ȳ»öÀ§Ãà(Áõ)(ÐáàõüÜßäê×õêñø) °£(ÊÜ)ÀÇ .
  • bean yellow mosaic virus
    ÄáȲ»öÁõ¸ðÀÚÀÌÅ©¹ÙÀÌ·¯½º
  • beet yellow mosaic virus
    ¹«¿ìȲ»öÁõ¹ÙÀÌ·¯½º
  • butter yellow
    ¹öÅÍȲ.
  • cadmium yellow
    Ä«µå¹ÅȲ(¡­üÜ).
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù.
  • subacute yellow atrophy of liver
    ¾Æ±Þ¼º °£È²»öÀ§Ãà(¡­ÊÜüÜßäê×õê).
  • subacute yellow atrophy of liver
    ¾Æ±Þ¼º °£È²»öÀ§Ãà(¡­ÊÜüÜßäê×õê)
  • visual yellow
    ½ÃȲ(ãÊüÜ).
  • visual yellow
    ½ÃȲ(ãÊüÜ)
  • xylene yellow S
    ÀÚÀÏ·»È²(¡­üÜ)S.
  • yellow atrophy
    Ȳ»öÀ§Ãà(¡­ê×õê)
  • yellow beeswax
    Ȳ¶ø(üÜÕÅ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EPI echo planar imaging; electronic portal imaging; Emotion Profile Index; epilepsy; epinephrine; epithe...
immun immune, immunity, immunization
IR drop of voltage across a resistor produced by a current; ileal resection; immune response; immunizat...
AYA acute yellow atrophy
AYV aster yellow virus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
B-Y Blue-on-yellow
DY Diamidino Yellow
DY Diamidino Yellow Dihydrochloride
Ay Lethal yellow
L.Y. Lucifer Yellow
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • childbed fever
    »ê¿å ¿­
  • continued fever
    °è·ù¿­
  • deer fly fever malady
    ¾ßÅ亴
    µ¿ÀǾî=tularemia.
  • dehydration fever
    Å»¼ö ¿­
  • double continued fever
    Áߺ¹ °è·ù ¿­
  • double quartan fever
    Áߺ¹ »çÀÏ ¿­
  • drug fever
    ¾à¹°¼º ¹ß¿­, Åõ¾à¿¡ ÀÇÇÑ ¹ß¿­, ¾à¹° ¿­
  • epidemic hemorrhagic fever
    À¯Ç༺ ÃâÇ÷ ¿­
    °í¿­¿¡ ÀÌ¾î ´Ü¹é ´¢³ª Àü½Å¼ºÀÇ ÃâÇ÷ °æÇâ µîÀ» º¸ÀÌ´Â ¹ÙÀÌ·¯½º¼º Àü¿°º´. Çѱ¹¿¡¼­ ¸Å³â ¹ß»ýÇϰí ÀÖ´Â ¹«¼­¿î Á¦2Á¾ ¹ýÁ¤ Àü¿°º´À¸·Î¼­, »ç¸Á·üÀÌ 7 %³ª µÇ¸ç ÇöÀç ±¹Á¦ÇÐȸ¿¡¼­´Â ½Å ÁõÈıº ÃâÇ÷ ¿­À̶ó ºÎ¸£Áö¸¸ À¯Ç༺ ÃâÇ÷ ¿­À̶ó´Â À̸§À¸·Î Áö³­ 40³â°£ ¾Ë·ÁÁ® ÀÖ¾úÀ¸¸ç, 6, 25ÀüÀï Á÷ÈÄ¿¡´Â Çѱ¹°ú ¹Ì±¹ÇÐÀÚµéÀÌ Çѱ¹Çü ÃâÇ÷ ¿­À̶ó°í ºÎ¸¥ ¶§µµ ÀÖ¾ú´Ù. ȯÀÚ´Â ³²ºÏÇÑÀ» ºñ·ÔÇÏ¿© Áß±¹
  • eruptive fever
    ¹ßÁø ¿­, ¸ÍÃâ ¿­
  • exanthematous fever
    ¹ßÁø ¿­
  • factitious fever
    Àΰø ¿­
  • familial Mediterranean fever
    °¡Á·¼º ÁöÁßÇØ ¿­
  • fever
    ¹ß¿­, ¿­, ¿­º´
    ü¿ÂÀÌ Á¤»ó ÀÌ»óÀ¸·Î »ó½ÂÇÏ´Â °Í. ¿øÀÎÀº ¹è¶õ, °©»ó¼± ºÐºñ °ú´Ù, °ú°ÝÇÑ À°Ã¼Àû ¿îµ¿ µî°ú °°Àº »ý¸®ÇÐÀû ½ºÆ®·¹½º¿¡ ÀÇÇϱ⵵ Çϰí, ¹Ì»ý¹°ÀÇ °¨¿°, ¿°Áõ µîÀÌ ¿øÀÎÀÌ µÇ±âµµ ÇÏ¸ç ¶ÇÇÑ ¹éÇ÷º´¿¡¼­¿Í °°ÀÌ ¹ß¿­ ¹°ÁúÀ» ¹æÃâÇÏ´Â ºñ°¨¿°¼º »óŵµ ¿øÀÎÀÌ µÈ´Ù.
  • fever thermometer
    ü¿Â±â
  • Haverhill fever
    ÇϺ£¸£Èú ¿­
    ¼­±³ÁõÀÇ ÇÑ ÇüÀÎ ±Þ¼º ¿­º´ÀÌ´Ù. ¶§·Î´Â ¿À¿°µÈ ¿ìÀ¯³ª ±× Á¦Ç°¿¡ ÀÇÇØ¼­µµ ÀüÆÄµÇ´Â µ¥ ±× ¿øÀÎÀº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
immunization, german measles See Immunization, MMR.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
immunization, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
immunization, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
immunization, h. flu See Immunization, HIB.
(12 Dec 1998)
immunization, hib This vaccine is to prevent disease caused by the haemophilus influenzae type b (hib) bacteria. The h. Influenzae (h. Flu) bacteria can cause a range of serious diseases including meningitis with potential brain damage and epiglottitis with airway obstruction poisoning. The hib vaccine is usually given at 2, 4 and 6 months of age. A final booster is given at 12-15 months of age. Hib vaccine rarely causes severe reactions.
(12 Dec 1998)
immunization, infectious hepatitis See Immunization, hepatitis a.
(12 Dec 1998)
immunization, influenza See Immunization, flu.
(12 Dec 1998)
immunization, measles See Immunization, MMR.
(12 Dec 1998)
immunization, mmr The standard vaccine given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most u.s. Colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
immunization, mumps See Immunization, MMR.
(12 Dec 1998)
immunization, passive Transfer of immunity from immunised to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (adoptive transfer).
(12 Dec 1998)
immunization, pneumococcal pneumonia This vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease (copd) or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children.
(12 Dec 1998)
immunization, polio The vaccines available for vaccination against polio are opv (oral polio vaccine) and ipv (inactivated polio vaccine). Opv is still the preferred vaccine for most children. As its name suggests, it is given by mouth. Ipv, or inactivated polio vaccine is given as a shot in the arm or leg. Infants and children should be given four doses of opv. The doses are given at 2 months, 4 months, 6-18 months and 4-6 years of age. Persons allergic to eggs or the drugs neomycin or streptomycin should receive opv, not the injectable ipv. Conversely, ipv should be given if the vaccine recipient is on long-term steroid (cortisone) therapy, has cancer, or is on chemotherapy or if a household member has aids or there is an unimmunised adult in the house.
(12 Dec 1998)
immunization program Organised services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Mediterranean fever
    ÁöÁßÇØ¿­(ÁöÁßÇØ ¿¬¾È Áö¹æ¿¡ ¹ß»ýÇÏ´Â °¢Á¾ ¿­º´,ƯÈ÷ »ç¶÷ÀÇ BRUCRLLOSIS)
  • Rocky Mountain spotted fever
    ·ÎŰ»ê È«¹Ý¿­(Áøµå±â°¡ ¸Å°³ÇÏ´Â º´)
  • blackwater fever
    Èæ¼ö¿­(¾Ç¼º ¸»¶ó¸®¾Æ)
  • brain fever
    ³ú¸·¿°
  • cabin fever
    ÃÊÁ¶;¼Ò¿Ü°¨;¹Ð½Ç °øÆ÷Áõ
  • camp fever
    ¾ß¿µÁö¿¡ ¹ß»ýÇÏ´Â ¿­º´(ƯÈ÷ ¹ßÁø ƼǪ½º)
  • enteric fever
    ÀåÆ¼Çª½º
  • fever
    ¿­ÀÌ ÀÖ´Â;¿­º´ÀÇ;¿­±¤ÀûÀÎ
  • fever
    ¿­;¿­º´;¿­±¤;¹ß¿­½ÃŰ´Ù
  • fever blister
    ´Ü¼ø Ç츣Æä½º
  • fever heat
    (¼·¾¾37µµ¸¦³Ñ´Â)½Å¿­;¿­±¤Àû ÈïºÐ
  • fever pitch
    º´Àû ÈïºÐ;¿­±¤
  • fever therapy
    ¹ß¿­ ¿ä¹ý
  • fever therapy
    ¹ß¿­¿ä¹ý
  • glandular fever
    ¼±¿­
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á